Hansa Biopharma AB (publ) (HNSBF) Stock Price, News & Analysis

Company Overview

Hansa Biopharma AB (publ) is a Sweden-based biopharmaceutical company specializing in the development and commercialization of immunomodulatory therapeutics for antibody-mediated diseases. The company’s leading product candidate, imlifidase (marketed as Idefirix® in Europe), is an enzyme treatment designed to cleave immunoglobulin G (IgG) antibodies and is being used to desensitize highly sensitized patients awaiting kidney transplantation. Hansa Biopharma’s proprietary IgG-degrading enzyme technology platform underpins a pipeline of potential therapies targeting rare autoimmune and transplant-related conditions where pathogenic antibodies play a central role.

Founded in 2003 and headquartered in Lund, Sweden, Hansa Biopharma has established operations across Europe and the United States, including a commercial presence in several key markets. The company secured European approval for Idefirix in 2020 and continues to pursue regulatory submissions and clinical trials to expand indications in both transplant medicine and rare immunological disorders. Hansa Biopharma collaborates with academic centers and specialty biopharma partners to explore additional applications of its imlifidase technology in areas such as neurology and hematology.

Hansa Biopharma’s pipeline also includes development programs for treatment of rare kidney diseases and autoimmune neuropathies, leveraging the same IgG-modulating mechanism of action. In addition to imlifidase, the company is advancing next-generation enzyme candidates and antibody-derived modalities to broaden its therapeutic reach. These efforts are supported by a multidisciplinary team of scientists, clinicians and industry veterans focused on translating cutting-edge research into novel therapies for patients with high unmet medical need.

Listed on Nasdaq Stockholm and trading over-the-counter in the U.S. under the symbol HNSBF, Hansa Biopharma combines academic roots with a growing commercial infrastructure. The company is led by an experienced management team and board of directors with deep expertise in biotechnology development and global regulatory affairs, positioning it to advance its pipeline and deliver innovative treatments to patients worldwide.

Key Stats

• Today's Range: $2.74 to $2.74
• 50-Day Range: $2.74 to $3.00
• 52-Week Range: $2.74 to $3.65
• Volume: 7,120 shs
• Average Volume: 1,800 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HNSBF Stock Analysis - Frequently Asked Questions

How have HNSBF shares performed this year?

Hansa Biopharma AB (publ)'s stock was trading at $3.00 at the start of the year. Since then, HNSBF shares have decreased by 8.7% and is now trading at $2.74.

How do I buy shares of Hansa Biopharma AB (publ)?

Shares of HNSBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/17/2025
• Next Earnings (Estimated): 7/17/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:HNSBF
• CIK: N/A
• Web: www.hansabiopharma.com
• Phone: 46 46 16 56 70
• Fax: N/A
• Employees: 146
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A